Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
For beginners, index investing provides broad diversification and low fees, making it easier to start building a long-term portfolio. Here’s a beginner-friendly overview to get you going.
21,008 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
A single chokepoint can reshape markets. When the strait hormuz closure sent oil prices higher, energy shares jumped ...
When a top executive sells a sizable stake, investors pay attention. This article unpacks the CFO's 50,000-share move...
A single quarterly filing can rewrite a fund’s star players. Tepper’s Appaloosa appears to have shifted away from NVI...
Medicare Part B costs soar for high-income retirees due to IRMAA. The two-year lookback means past income spikes stil...
PureCycle (PCT) is expanding its recycling footprint, and the Q4 2025 earnings call could reshape how investors value...
February delivered a surprising 10% rise for Sandisk stock, even without a major company catalyst. This guide breaks ...
A bold bet on the future of critical minerals. This article breaks down what metals company (tmc) could mean for your...
A recent SEC filing shows Tabor Asset Management increasing its stake in Madison Square Garden Sports, underscoring a...
A Tuesday uptick in Edgewise Therapeutics stock topped the market, driven by an upbeat price target from a major bank...
A steep stock drop can force tough choices. This article analyzes why a full exit from Cogent could matter to investo...
Astera Labs sits at a pivotal point in the data center supply chain. This article breaks down why the stock could ris...